

**LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN- lansoprazole,  
amoxicillin and clarithromycin  
Sandoz Inc**

-----  
***triple therapy***

**Lansoprazole Delayed-Release Capsules USP, 30 mg**

**Amoxicillin Capsules USP, 500 mg**

**Clarithromycin Tablets USP, 500 mg**

**Rx Only**

To reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg and other antibacterial drugs, lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.


THESE PRODUCTS ARE INTENDED ONLY FOR USE AS DESCRIBED. The individual products contained in this package should not be used alone or in combination for other purposes. The information described in this labeling concerns only the use of these products as indicated in this daily administration pack. For information on use of the individual components when dispensed as individual medications outside this combined use for treating *Helicobacter pylori* (*H. pylori*), please see the package inserts for each individual product.

**DESCRIPTION**

*triple therapy* Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg consists of a daily administration card containing two lansoprazole 30 mg delayed-release capsules USP, four amoxicillin 500 mg capsules USP, and two clarithromycin 500 mg tablets USP, for oral administration.

**Lansoprazole Delayed-Release Capsules USP**

The active ingredient in lansoprazole delayed-release capsules USP is lansoprazole, a substituted benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl] methyl] sulfinyl] benzimidazole, a proton pump inhibitor. Its molecular formula is  $C_{16}H_{14}F_3N_3O_2S$  with a molecular weight of 369.37. Lansoprazole has the following structure:




Lansoprazole is a white to brownish-white odorless crystalline powder which melts with decomposition at approximately 166°C. Lansoprazole is freely soluble in dimethylformamide; soluble in methanol; sparingly soluble in ethanol; slightly soluble in ethyl acetate, dichloromethane and acetonitrile; very slightly soluble in ether; and practically insoluble in hexane and water.

Each delayed-release capsule contains enteric-coated granules consisting of 30 mg of lansoprazole (active ingredient) and the following inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium carbonate, methacrylic acid copolymer dispersion, polyethylene glycol, sugar spheres (contains maize starch and sucrose), talc and titanium dioxide. Components of the hypromellose capsule include carrageenan, hypromellose, potassium chloride and titanium dioxide. The capsule is printed with edible black ink containing carnauba wax, FD & C blue # 2 aluminum lake, glyceryl monooleate, red ferric oxide, shellac, yellow ferric oxide.

### Amoxicillin Capsules USP

Amoxicillin is a penicillin class antibacterial, an analog of ampicillin, with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Chemically it is (2S, 5R, 6R)-6-[(R)-(-)-2-amino-2-(p-hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo [3.2.0] heptane-2-carboxylic acid trihydrate. The molecular formula is  $C_{16}H_{19}N_3O_5S \cdot 3H_2O$  and the molecular weight is 419.45. Amoxicillin has the following structure:



Amoxicillin capsules are intended for oral administration. Each yellow opaque capsule contains amoxicillin trihydrate equivalent to 500 mg of amoxicillin. Inactive ingredients: Capsule shells - yellow ferric oxide, titanium dioxide, gelatin, black ferric oxide, shellac, propylene glycol, potassium hydroxide and ammonium hydroxide; Capsule contents - cellulose microcrystalline and magnesium stearate. Meets USP Dissolution Test 2.

### **Clarithromycin Tablets USP**

Clarithromycin is a macrolide antimicrobial. Chemically, it is 6-O-methylerythromycin. The molecular formula is  $C_{38}H_{69}NO_{13}$ , and the molecular weight is 747.96. Clarithromycin has the following structure:

Clarithromycin is a white to off-white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in water. Each white oval film-coated immediate-release tablet contains 500 mg of clarithromycin and the following inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, povidone, talc and titanium dioxide.

## **CLINICAL PHARMACOLOGY**

### **Pharmacokinetics**

Pharmacokinetics when all three components (lansoprazole capsules, amoxicillin capsules, clarithromycin tablets) were co-administered has not been studied. Studies have shown no clinically significant interactions of lansoprazole and amoxicillin or lansoprazole and clarithromycin when administered together. There is no information about the gastric mucosal concentrations of lansoprazole, amoxicillin and clarithromycin after administration of these agents concomitantly. The systemic pharmacokinetic

information presented below is based on studies in which each product was administered alone.

## **Lansoprazole**

### *Absorption*

Lansoprazole capsules contain an enteric-coated granule formulation of lansoprazole (because lansoprazole is acid-labile), so that absorption of lansoprazole begins only after the granules leave the stomach. The mean peak plasma levels of lansoprazole occur at approximately 1.7 hours. After a single-dose administration of 15 to 60 mg of oral lansoprazole, the peak plasma concentrations ( $C_{max}$ ) of lansoprazole and the area under the plasma concentration curves (AUCs) of lansoprazole were approximately proportional to the administered dose. Lansoprazole does not accumulate and its pharmacokinetics are unaltered by multiple dosing. The absolute bioavailability is over 80%. In healthy subjects, the mean ( $\pm$ SD) plasma half-life was 1.5 ( $\pm$ 1.0) hours. Both the  $C_{max}$  and AUC are diminished by about 50 to 70% if lansoprazole is given 30 minutes after food, compared to the fasting condition. There is no significant food effect if lansoprazole is given before meals.

### *Distribution*

Lansoprazole is 97% bound to plasma proteins. Plasma protein binding is constant over the concentration range of 0.05 to 5 mcg/mL

### *Elimination*

### Metabolism

Lansoprazole is extensively metabolized in the liver. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by blocking the proton pump [ $(H^+, K^+)$ -ATPase enzyme system] at the secretory surface of the gastric parietal cell. The two active species are not present in the systemic circulation. The plasma elimination half-life of lansoprazole is less than two hours while the acid inhibitory effect lasts more than 24 hours. Therefore, the plasma elimination half-life of lansoprazole does not reflect its duration of suppression of gastric acid secretion.

### Excretion

Following single-dose oral administration of lansoprazole, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of  $^{14}C$ -lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites.

## **Amoxicillin**

### *Absorption*

Amoxicillin is stable in the presence of gastric acid and may be given without regard to meals. It is rapidly absorbed after oral administration. Orally administered doses of 500 mg amoxicillin capsules result in average peak blood levels one to two hours after

administration in the range of 5.5 to 7.5 mcg/mL

### *Distribution*

Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed. In blood serum, amoxicillin is approximately 20% protein-bound.

### *Metabolism/Elimination*

The elimination half-life of amoxicillin is 61.3 minutes. Detectable serum levels are observed up to eight hours after an orally administered dose of amoxicillin. Approximately 60% of the orally administered dose of amoxicillin is excreted unchanged in the urine within six to eight hours post-dose; its excretion can be delayed by concurrent administration of probenecid.

## **Clarithromycin**

### *Absorption*

Clarithromycin is rapidly absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%. For a single 500 mg dose of clarithromycin, food slightly delays the onset of clarithromycin absorption, increasing the peak time from approximately two to 2.5 hours. Food also increases the clarithromycin peak plasma concentration by about 24%, but does not affect the extent of clarithromycin bioavailability. Food does not affect the onset of formation of the antimicrobially active metabolite, 14-OH clarithromycin or its peak plasma concentration but does slightly decrease the extent of metabolite formation, indicated by an 11% decrease in area under the plasma concentration-time curve (AUC). Therefore, clarithromycin tablets may be given without regard to food.

In nonfasting, healthy human subjects (males and females), peak plasma concentrations were attained within two to three hours after oral dosing. Steady-state peak plasma clarithromycin concentrations were attained within three days and were approximately 3 to 4 mcg/mL with a 500 mg dose administered every eight to 12 hours.

### *Metabolism/Elimination*

The elimination half-life of clarithromycin was five to seven hours with 500 mg administered every eight to 12 hours. The nonlinearity of clarithromycin pharmacokinetics is slight at the recommended dose of 500 mg administered every eight to 12 hours. With a 500 mg every eight to 12 hours dosing, the peak steady-state concentration of 14-OH clarithromycin is up to 1 mcg/mL, and its elimination half-life is about seven to nine hours. The steady-state concentration of this metabolite is generally attained within three to four days.

After a 500 mg tablet every 12 hours, the urinary excretion of clarithromycin is approximately 30%. The renal clearance of clarithromycin approximates the normal glomerular filtration rate. The major metabolite found in urine is 14-OH clarithromycin, which accounts for an additional 10 to 15% of the dose with a 500 mg tablet administered every 12 hours.

Steady-state concentrations of clarithromycin and 14-OH clarithromycin observed following administration of 500 mg doses of clarithromycin every 12 hours to adult

patients with HIV infection were similar to those observed in healthy volunteers. In adult HIV-infected patients taking 500 mg doses of clarithromycin every 12 hours, steady-state clarithromycin  $C_{max}$  values ranged from 2 to 4 mcg/mL.

The steady-state concentrations of clarithromycin in subjects with impaired hepatic function did not differ from those in normal subjects; however, the 14-OH clarithromycin concentrations were lower in the hepatically impaired subjects. The decreased formation of 14-OH clarithromycin was at least partially offset by an increase in renal clearance of clarithromycin in the subjects with impaired hepatic function when compared to healthy subjects.

The pharmacokinetics of clarithromycin was also altered in subjects with impaired renal function (see **PRECAUTIONS** and **DOSAGE AND ADMINISTRATION**).

Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids. There are no data available on cerebrospinal fluid penetration. Because of high intracellular concentrations, tissue concentrations are higher than serum concentrations.

## **Specific Populations**

### ***Geriatric Patients***

The clearance of lansoprazole is decreased in the elderly, with elimination half-life increased approximately 50 to 100%. Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole. Peak plasma levels were not increased in the elderly.

### ***Male and Female Patients***

In a study comparing 12 male and six female human subjects who received lansoprazole, no sex related differences were found in pharmacokinetics and intragastric pH results.

### ***Racial or Ethnic Groups***

The pooled mean pharmacokinetic parameters of lansoprazole from twelve U.S. studies (N=513) were compared to the mean pharmacokinetic parameters from two Asian studies (N=20). The mean AUCs of lansoprazole in Asian subjects were approximately twice those seen in pooled U.S. data; however, the inter-individual variability was high. The  $C_{max}$  values were comparable.

### ***Patients with Renal Impairment***

In patients with severe renal impairment, plasma protein binding decreased by 1 to 1.5% after administration of 60 mg of lansoprazole. Patients with renal impairment had a shortened elimination half-life and decreased total AUC (free and bound). The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the  $C_{max}$  and  $T_{max}$  (time to reach the maximum concentration) were not different than the  $C_{max}$  and  $T_{max}$  from subjects with normal renal function. Therefore, the pharmacokinetics of lansoprazole were not clinically different in patients with mild, moderate or severe renal impairment compared to healthy subjects with normal renal function.

### ***Patients with Hepatic Impairment***

In patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment there was an approximate 3-fold increase in mean AUC compared to healthy subjects with normal hepatic function following multiple oral doses of 30 mg lansoprazole for 7 days. The corresponding mean plasma half-life of lansoprazole was prolonged from 1.5 hours to 4 hours (Child-Pugh A) or 5 hours (Child-Pugh B).

In patients with compensated and decompensated cirrhosis, there was an approximate 6- and 5-fold increase in AUC, respectively, compared to healthy subjects with normal hepatic function following a single oral dose of 30 mg lansoprazole (see **DOSAGE AND ADMINISTRATION**).

## **Drug Interaction Studies**

### *Effect of Lansoprazole on Other Drugs*

#### **Cytochrome P450 Interactions**

Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes. Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, or clarithromycin in healthy subjects. These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.

#### **Theophylline**

When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen. Because of the small magnitude and the direction of the effect on theophylline clearance, this interaction is unlikely to be of clinical concern (see **PRECAUTIONS, Drug Interactions**).

#### **Methotrexate and 7-hydroxymethotrexate**

In an open-label, single-arm, eight day, pharmacokinetic study of 28 adult rheumatoid arthritis patients (who required the chronic use of 7.5 to 15 mg of methotrexate given weekly), administration of seven days of naproxen 500 mg twice daily and lansoprazole 30 mg daily had no effect on the pharmacokinetics of methotrexate and 7-hydroxymethotrexate. While this study was not designed to assess the safety of this combination of drugs, no major adverse reactions were noted. However, this study was conducted with low doses of methotrexate. A drug interaction study with high doses of methotrexate has not been conducted (see **WARNINGS**).

#### **Amoxicillin**

Lansoprazole has also been shown to have no clinically significant interaction with amoxicillin.

#### **Sucralfate**

In a single-dose crossover study examining lansoprazole 30 mg administered alone and concomitantly with sucralfate 1 gram, absorption of lansoprazole was delayed and the bioavailability was reduced by 17% when administered concomitantly with sucralfate (see **PRECAUTIONS, Drug Interactions**).

#### **Antacids**

In clinical trials, antacids were administered concomitantly with lansoprazole and there was no evidence of a change in the efficacy of lansoprazole.

### **Clopidogrel**

Clopidogrel is metabolized to its active metabolite in part by CYP2C19. A study of healthy subjects who were CYP2C19 extensive metabolizers, receiving once daily administration of clopidogrel 75 mg alone or concomitantly with lansoprazole 30 mg (n=40), for nine days was conducted. The mean AUC of the active metabolite of clopidogrel was reduced by approximately 14% (mean AUC ratio was 86%, with 90% CI of 80 to 92%) when lansoprazole was co-administered compared to administration of clopidogrel alone.

Pharmacodynamic parameters were also measured and demonstrated that the change in inhibition of platelet aggregation (induced by 5 mcM ADP) was related to the change in the exposure to clopidogrel active metabolite. The effect on exposure to the active metabolite of clopidogrel and on clopidogrel induced platelet inhibition is not considered clinically important.

#### *Effect of Other Drugs on Lansoprazole*

Because lansoprazole is metabolized by CYP2C19 and CYP3A4, inducers and inhibitors of these enzymes may potentially alter exposure of lansoprazole.

## **Pharmacodynamics**

### **Microbiology**

Lansoprazole, clarithromycin and/or amoxicillin have been shown to be active against most strains of *Helicobacter pylori* *in vitro* and in clinical infections as described in the **INDICATIONS AND USAGE** section.

### **Helicobacter pylori Pretreatment Resistance**

Clarithromycin pretreatment resistance rates were 9.5% (91/960) by E-test and 11.3% (12/106) by agar dilution in the dual and triple therapy clinical trials (M93-125, M93-130, M93-131, M95-392, and M95-399).

Amoxicillin pretreatment susceptible isolates ( $\leq 0.25$  mcg/mL) occurred in 97.8% (936/957) and 98.0% (98/100) of the patients in the dual and triple therapy clinical trials by E-test and agar dilution, respectively. Twenty-one of 957 patients (2.2%) by E-test, and two of 100 patients (2.0%) by agar dilution, had amoxicillin pretreatment MICs of greater than 0.25 mcg/mL. One patient on the 14-day triple therapy regimen had an unconfirmed pretreatment amoxicillin minimum inhibitory concentration (MIC) of greater than 256 mcg/mL by E-test and the patient was eradicated of *H. pylori*.

**Table 1: Clarithromycin Susceptibility Test Results and Clinical/Bacteriological Outcomes\***

<b>Clarithromycin Pretreatment Results</b>		<b>Clarithromycin Post-treatment Results</b>	
		<b><i>H. pylori</i> negative-</b>	<b><i>H. pylori</i> positive -not eradicated Post-treatment</b>

		eradicated	susceptibility results			
			S <sup>†</sup>	I <sup>†</sup>	R <sup>†</sup>	No MIC
<b>Triple Therapy 14-Day (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily) (M95-399, M93-131, M95-392)</b>						
Susceptible <sup>†</sup>	112	105				7
Intermediate <sup>†</sup>	3	3				
Resistant <sup>†</sup>	17	6			7	4
<b>Triple Therapy 10-Day (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily) (M95-399)</b>						
Susceptible <sup>†</sup>	42	40	1		1	
Intermediate <sup>†</sup>						
Resistant <sup>†</sup>	4	1			3	

\* Includes only patients with pretreatment clarithromycin susceptibility test results

† Breakpoints for antimicrobial susceptibility testing at the time of the studies were: Susceptible (S) MIC ≤0.25 mcg/mL, Intermediate (I) MIC 0.5 to 1.0 mcg/mL, Resistant (R) MIC ≥2 mcg/mL. For current performance standards for antimicrobial susceptibility testing, see section below title, **Susceptibility Test for *Helicobacter pylori***.

Patients not eradicated of *H. pylori* following lansoprazole/amoxicillin/clarithromycin triple therapy will likely have clarithromycin resistant *H. pylori* isolates. Therefore, for those patients who fail therapy, clarithromycin susceptibility testing should be done if possible. Patients with clarithromycin resistant *H. pylori* should not be treated with lansoprazole/amoxicillin/clarithromycin triple therapy or other regimens which include clarithromycin as the sole antimicrobial agent.

### **Amoxicillin Susceptibility Test Results and Clinical/Bacteriological Outcomes**

In the dual and triple therapy clinical trials, 82.6% (195/236) of the patients that had pretreatment amoxicillin susceptible MICs (≤0.25 mcg/mL) were eradicated of *H. pylori*. Of those with pretreatment amoxicillin MICs of greater than 0.25 mcg/mL, three of six had the *H. pylori* eradicated. A total of 30% (21/70) of the patients failed lansoprazole 30 mg three times daily per amoxicillin 1 g three times daily dual therapy and a total of 12.8% (22/172) of the patients failed the 10 and 14 day triple therapy regimens. Post-treatment susceptibility results were not obtained on 11 of the patients who failed therapy. Nine of the 11 patients with amoxicillin post-treatment MICs that failed the triple therapy regimen also had clarithromycin resistant *H. pylori* isolates.

### **Susceptibility Test for *Helicobacter pylori***

The reference methodology for susceptibility testing of *H. pylori* is agar dilution MICs.<sup>1</sup> One to three microliters of an inoculum equivalent to a No. 2 McFarland standard (1 x 10<sup>7</sup> -1 x 10<sup>8</sup> CFU/mL for *H. pylori*) are inoculated directly onto freshly prepared antimicrobial containing Mueller-Hinton agar plates with 5% aged defibrinated sheep blood (greater than two weeks old). The agar dilution plates are incubated at 35°C in a microaerobic environment produced by a gas generating system suitable for *Campylobacter* species. After three days of incubation, the MICs are recorded as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The clarithromycin and amoxicillin MIC values should be interpreted according to the following criteria

<b>Susceptibility Test Interpretive Criteria for <i>H. pylori</i></b>	
<b>Clarithromycin MIC (mcg/mL)*</b>	<b>Interpretation</b>
≤0.25	Susceptible (S)
0.5	Intermediate (I)
≥1.0	Resistant (R)
<b>Susceptibility Test Interpretive Criteria for <i>H. pylori</i></b>	
<b>Amoxicillin MIC (mcg/mL)*†</b>	<b>Interpretation</b>
< 0.25	Susceptible (S)

\* These are tentative breakpoints for the agar dilution methodology and should not be used to interpret results obtained using alternative methods.

† There were not enough organisms with MICs greater than 0.25 mcg/mL to determine a resistance breakpoint.

Standardized susceptibility test procedures require the use of laboratory control bacteria to monitor and ensure the accuracy and precision of supplies and reagents in the assay, and the techniques of the individual performing the test. Standard clarithromycin or amoxicillin powder should provide the following MIC ranges.

<b>Acceptable Quality Control Ranges</b>	<b>Antimicrobial Agent</b>	<b>MIC (mcg/mL)*</b>
<i>H. pylori</i> ATCC 43504	Clarithromycin	0.015 - 0.12
<i>H. pylori</i> ATCC 43504	Amoxicillin	0.015 - 0.12

\* These are quality control ranges for the agar dilution methodology and should not be used to control test results obtained using alternative methods.

### **Antisecretory Activity**

After oral administration, lansoprazole was shown to significantly decrease the basal acid output and significantly increase the mean gastric pH and percent of time the gastric pH was greater than three and greater than four. Lansoprazole also significantly reduced meal stimulated gastric acid output and secretion volume, as well as pentagastrin-stimulated acid output. In patients with hypersecretion of acid, lansoprazole significantly reduced basal and pentagastrin-stimulated gastric acid secretion. Lansoprazole inhibited the normal increases in secretion volume, acidity and acid output induced by insulin.

The intragastric pH results of a five-day, pharmacodynamic, crossover study of 15 mg and 30 mg of once daily lansoprazole are presented in **Table 2**.

**Table 2: Mean Antisecretory Effects after Single and Multiple Daily Lansoprazole Dosing**

<b>Parameter</b>	<b>Baseline Value</b>	<b>Lansoprazole</b>			
		<b>15 mg</b>		<b>30 mg</b>	
		<b>Day 1</b>	<b>Day 5</b>	<b>Day 1</b>	<b>Day 5</b>
Mean 24-Hour pH	2.1	2.7*	4*	3.6†	4.9†
Mean Nighttime Hour pH	1.9	2.4	3*	2.6	3.8†

% Time Gastric pH>3	18	33*	59*	51†	72†
% Time Gastric pH>4	12	22*	49*	41†	66†

NOTE: An intragastric pH of greater than 4 reflects a reduction in gastric acid by 99%.

\* (p<0.05) versus baseline only.

† (p<0.05) versus baseline and lansoprazole 15 mg.

After the initial dose in this study, increased gastric pH was seen within one to two hours with 30 mg of lansoprazole and two to three hours with 15 mg of lansoprazole. After multiple daily dosing, increased gastric pH was seen within the first hour post-dosing with 30 mg of lansoprazole and within one to two hours post-dosing with 15 mg of lansoprazole.

Acid suppression may enhance the effect of antimicrobials in eradicating *Helicobacter pylori* (*H. pylori*). The percentage of time gastric pH was elevated above five and six was evaluated in a crossover study of lansoprazole given daily, twice daily and three times daily.

**Table 3: Mean Antisecretory Effects After Five Days of Twice Daily and Three Times Daily Dosing**

Parameter	Lansoprazole			
	30 mg daily	15 mg twice daily	30 mg twice daily	30 mg three times daily
% Time Gastric pH>5	43	47	59*	77†
% Time Gastric pH>6	20	23	28	45†

\* (p<0.05) versus lansoprazole 30 mg daily

† (p<0.05) versus lansoprazole 30 mg daily, 15 mg twice daily and 30 mg twice daily.

The inhibition of gastric acid secretion as measured by intragastric pH gradually returned to normal over two to four days after multiple doses. There was no indication of rebound gastric acidity.

### **Enterochromaffin-like (ECL) Cell Effects**

During lifetime exposure of rats with up to 150 mg/kg/day of lansoprazole dosed seven days per week, marked hypergastrinemia was observed followed by ECL cell proliferation and formation of carcinoid tumors, especially in female rats. Gastric biopsy specimens from the body of the stomach from approximately 150 patients treated continuously with lansoprazole for at least one year did not show evidence of ECL cell effects similar to those seen in rat studies. Longer term data are needed to rule out the possibility of an increased risk of the development of gastric tumors in patients receiving long-term therapy with lansoprazole (see **PRECAUTIONS, Carcinogenesis, Mutagenesis, Impairment of Fertility**).

### **Other Gastric Effects in Humans**

Lansoprazole did not significantly affect mucosal blood flow in the fundus of the stomach. Due to the normal physiologic effect caused by the inhibition of gastric acid

secretion, a decrease of about 17% in blood flow in the antrum, pylorus, and duodenal bulb was seen. Lansoprazole significantly slowed the gastric emptying of digestible solids. Lansoprazole increased serum pepsinogen levels and decreased pepsin activity under basal conditions and in response to meal stimulation or insulin injection. As with other agents that elevate intragastric pH, increases in gastric pH were associated with increases in nitrate-reducing bacteria and elevation of nitrite concentration in gastric juice in patients with gastric ulcer. No significant increase in nitrosamine concentrations was observed.

### ***Serum Gastrin Effects***

In over 2100 patients, median fasting serum gastrin levels increased 50 to 100% from baseline but remained within normal range after treatment with 15 to 60 mg of oral lansoprazole. These elevations reached a plateau within two months of therapy and returned to pretreatment levels within four weeks after discontinuation of therapy.

Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum CgA levels. The increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumors (see **WARNINGS**).

### ***Endocrine Effects***

Human studies for up to one year have not detected any clinically significant effects on the endocrine system. Hormones studied include testosterone, luteinizing hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEA-S), prolactin, cortisol, estradiol, insulin, aldosterone, parathormone, glucagon, thyroid stimulating hormone (TSH), triiodothyronine (T<sub>3</sub>), thyroxine (T<sub>4</sub>), and somatotrophic hormone (STH). Lansoprazole in oral doses of 15 to 60 mg for up to one year had no clinically significant effect on sexual function. In addition, lansoprazole in oral doses of 15 to 60 mg for two to eight weeks had no clinically significant effect on thyroid function. In 24 month carcinogenicity studies in Sprague-Dawley rats with daily lansoprazole dosages up to 150 mg/kg, proliferative changes in the Leydig cells of the testes, including benign neoplasm, were increased compared to control rats.

### ***Other Effects***

No systemic effects of lansoprazole on the central nervous system, lymphoid, hematopoietic, renal, hepatic, cardiovascular, or respiratory systems have been found in humans. Among 56 patients who had extensive baseline eye evaluations, no visual toxicity was observed after lansoprazole treatment (up to 180 mg/day) for up to 58 months. After lifetime lansoprazole exposure in rats, focal pancreatic atrophy, diffuse lymphoid hyperplasia in the thymus, and spontaneous retinal atrophy were seen.

## **CLINICAL STUDIES**

### ***H. pylori* Eradication to Reduce the Risk of Duodenal Ulcer Recurrence**

Randomized, double-blind clinical studies performed in the U.S. in patients with *H. pylori* and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within one year) evaluated the efficacy of lansoprazole, amoxicillin and clarithromycin as triple 14-day therapy for the eradication of *H. pylori*. The triple therapy regimen (lansoprazole 30 mg twice daily/amoxicillin 1 g twice daily/clarithromycin 500 mg twice daily) produced

statistically significantly higher eradication rates than lansoprazole plus amoxicillin, lansoprazole plus clarithromycin, and amoxicillin plus clarithromycin dual therapies.

*H. pylori* eradication was defined as two negative tests (culture and histology) at four to six weeks following the end of treatment.

Triple therapy was shown to be more effective than all possible dual therapy combinations. The combination of lansoprazole plus amoxicillin and clarithromycin as triple therapy was effective in eradicating *H. pylori*. Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence.

A randomized, double-blind clinical study performed in the U.S. in patients with *H. pylori* and duodenal ulcer disease (defined as an active ulcer or history of an ulcer within one year) compared the efficacy of lansoprazole triple therapy for ten and 14 days. This study established that the 10-day triple therapy was equivalent to the 14-day triple therapy in eradicating *H. pylori*.

**Table 4: *H. pylori* Eradication Rates - Triple Therapy (lansoprazole/amoxicillin/clarithromycin) Percent of Patients Cured [95% Confidence Interval] (Number of patients)**

Study	Duration	Triple Therapy Evaluable Analysis*	Triple Therapy Intent-to-Treat Analysis†
M93-131	14 days	92‡ [80.0-97.7] (N=48)	86‡ [73.3-93.5] (N=55)
M95-392	14 days	86§ [75.7-93.6] (N=66)	83§ [72.0-90.8] (N=70)
M95-399¶	14 days	85 [77.0-91.0] (N=113)	82 [73.9-88.1] (N=126)
	10 days	84 [76.0-89.8] (N=123)	81 [73.9-87.6] (N=135)

\* Based on evaluable patients with confirmed duodenal ulcer (active or within one year) and *H. pylori* infection at baseline defined as at least two of three positive endoscopic tests from CLOtest, histology and/or culture. Patients were included in the analysis if they completed the study. Additionally, if patients dropped out of the study due to an adverse event related to the study drug, they were included in the evaluable analysis as failures of therapy.

† Patients were included in the analysis if they had documented *H. pylori* infection at baseline as defined above and had a confirmed duodenal ulcer (active or within one year). All dropouts were included as failures of therapy.

‡ ( $p < 0.05$ ) versus lansoprazole/amoxicillin and lansoprazole/clarithromycin dual therapy.

§ ( $p < 0.05$ ) versus clarithromycin/amoxicillin dual therapy.

¶ The 95% confidence interval for the difference in eradication rates, 10 day minus 14 day is (-10.5, 8.1) in the evaluable analysis and (-9.7, 9.1) in the intent-to-treat analysis.

## INDICATIONS AND USAGE

### *H. pylori* Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

The components in lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg (lansoprazole, amoxicillin, and clarithromycin) are indicated for the treatment of patients with *H. pylori* infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate *H. pylori*. Eradication of *H. pylori* has been shown to reduce the risk of duodenal ulcer recurrence (see **CLINICAL STUDIES** and **DOSAGE AND ADMINISTRATION**).

To reduce the development of drug-resistant bacteria and maintain the effectiveness of lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg and other antibacterial drugs, lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

## CONTRAINDICATIONS

Triple therapy of lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg is contraindicated in patients with known severe hypersensitivity to any component of the formulation of lansoprazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, and urticaria (see **ADVERSE REACTIONS**). Proton Pump Inhibitors (PPIs), including lansoprazole are contraindicated with rilpivirine-containing products (see **CLINICAL PHARMACOLOGY**, Drug Interaction Studies).

A history of severe hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or other beta-lactam antibiotics (e.g., penicillins and cephalosporins) is a contraindication.

Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics.

Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin.

Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including *torsades de pointes*.

Concomitant administration of clarithromycin, a component of lansoprazole, amoxicillin and clarithromycin, and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine, ergotamine or dihydroergotamine (see **PRECAUTIONS, Drug Interactions**). There have been post-marketing reports of drug interactions when clarithromycin and/or erythromycin are co-administered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and *torsades de pointes*) most likely due to inhibition of metabolism of these drugs by erythromycin and clarithromycin. Fatalities have been reported.

Concomitant administration of clarithromycin and colchicine is contraindicated in patients

with renal or hepatic impairment.

Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis (see **WARNINGS**).

## **WARNINGS**

### **Acute Hypersensitivity Reactions**

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), and Henoch-Schonlein purpura lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg should be discontinued immediately and appropriate treatment should be urgently initiated.

### **Use in Pregnancy**

**CLARITHROMYCIN SHOULD NOT BE USED IN PREGNANT WOMEN EXCEPT IN CLINICAL CIRCUMSTANCES WHERE NO ALTERNATIVE THERAPY IS APPROPRIATE. IF PREGNANCY OCCURS WHILE TAKING CLARITHROMYCIN, THE PATIENT SHOULD BE INFORMED OF THE POTENTIAL HAZARD TO THE FETUS. CLARITHROMYCIN HAS DEMONSTRATED ADVERSE EFFECTS OF PREGNANCY OUTCOME AND/OR EMBRYO-FETAL DEVELOPMENT IN MONKEYS, RATS, MICE, AND RABBITS AT DOSES THAT PRODUCED PLASMA LEVELS TWO TO 17 TIMES THE SERUM LEVELS ACHIEVED IN HUMANS TREATED AT THE MAXIMUM RECOMMENDED HUMAN DOSES (see PRECAUTIONS, Pregnancy).**

### **Hepatotoxicity**

Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications. Symptoms of hepatitis can include anorexia, jaundice, dark urine, pruritus, or tender abdomen. Discontinue clarithromycin immediately if signs and symptoms of hepatitis occur.

### **QT Prolongation**

Clarithromycin has been associated with prolongation of the QT interval and infrequent

cases of arrhythmia. Cases of *torsades de pointes* have been spontaneously reported during postmarketing surveillance in patients receiving clarithromycin. Fatalities have been reported. Clarithromycin should be avoided in patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia (see **CONTRAINDICATIONS**) and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. Elderly patients may be more susceptible to drug-associated effects on the QT interval.

### **Presence of Gastric Malignancy**

In adults, symptomatic response to therapy with lansoprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI. In older patients, also consider an endoscopy.

### **Acute Interstitial Nephritis**

Acute interstitial nephritis (AIN) has been observed in patients taking proton pump inhibitors (PPIs) including lansoprazole. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue lansoprazole if AIN develops (see **CONTRAINDICATIONS**).

### **Cutaneous and Systemic Lupus Erythematosus**

Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs, including lansoprazole. These events have occurred as both new onset and an exacerbation of existing autoimmune disease. The majority of PPI-induced lupus erythematosus cases were CLE.

The most common form of CLE reported in patients treated with PPIs was subacute CLE (SCLE) and occurred within weeks to years after continuous drug therapy in patients ranging from infants to the elderly. Generally, histological findings were observed without organ involvement.

Systemic lupus erythematosus (SLE) is less commonly reported than CLE in patients receiving PPIs. PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment primarily in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported.

Avoid administration of PPIs for longer than medically indicated. If signs or symptoms consistent with CLE or SLE are noted in patients receiving lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with discontinuation of the PPI alone in four to 12 weeks. Serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.

### **Drug Interactions**

Serious adverse reactions have been reported in patients taking clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia with

disopyramide, and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older (see **CONTRAINDICATIONS** and **PRECAUTIONS, Drug Interactions**). Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see **PRECAUTIONS, Drug Interactions**).

### Colchicine

Life-threatening and fatal drug interactions have been reported in patients treated with clarithromycin and colchicine. Clarithromycin is a strong CYP3A4 inhibitor and this interaction may occur while using both drugs at their recommended doses. If co-administration of clarithromycin and colchicine is necessary in patients with normal renal and hepatic function, the dose of colchicine should be reduced. Patients should be monitored for clinical symptoms of colchicine toxicity. Concomitant administration of clarithromycin and colchicine is contraindicated in patients with renal or hepatic impairment (see **CONTRAINDICATIONS** and **PRECAUTIONS, Drug Interactions**).

### Benzodiazepines

Increased sedation and prolongation of sedation have been reported with concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam, and midazolam.

### Oral Hypoglycemic Agents/Insulin

The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycemia when used concomitantly. Careful monitoring of glucose is recommended.

### Oral Anticoagulants

There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin. INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.

### HMG-CoA Reductase Inhibitors (statins)

Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated (see **CONTRAINDICATIONS**) as these statins are extensively metabolized by CYP3A4, and concomitant treatment with clarithromycin increases their plasma concentration, which increases the risk of myopathy, including rhabdomyolysis. Cases of rhabdomyolysis have been reported in patients taking clarithromycin concomitantly with these statins. If treatment with clarithromycin cannot be avoided, therapy with lovastatin or simvastatin must be suspended during the course of treatment.

Caution should be exercised when prescribing clarithromycin with statins. In situations where the concomitant use of clarithromycin with atorvastatin or pravastatin cannot be avoided, atorvastatin dose should not exceed 20 mg daily and pravastatin dose should

not exceed 40 mg daily. Use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin) can be considered. It is recommended to prescribe the lowest registered dose if concomitant use cannot be avoided.

### Interactions with Investigations for Neuroendocrine Tumors

Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Healthcare providers should temporarily stop lansoprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary (see **CLINICAL PHARMACOLOGY**, Drug Interaction Studies).

### Interaction with Methotrexate

Literature suggests that concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients (see **CLINICAL PHARMACOLOGY**, Drug Interaction Studies).

### Clostridium Difficile-Associated Diarrhea

*Clostridium difficile* associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clarithromycin and/or amoxicillin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

In addition, published observational studies suggest that PPI therapy, may be associated with an increased risk of CDAD, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve.

## PRECAUTIONS

### General

The possibility of superinfections with fungal or bacterial pathogens should be considered during therapy. If superinfections occur, lansoprazole delayed-release

capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg should be discontinued and appropriate therapy instituted.

Prescribing lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Clarithromycin is principally excreted via the liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate.

Exacerbation of symptoms of myasthenia gravis and new onset of symptoms of myasthenic syndrome has been reported in patients receiving clarithromycin therapy.

### **Information for Patients**

Each dose of lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg contains four pills: one white capsule (lansoprazole), two yellow capsules (amoxicillin) and one white tablet (clarithromycin). Each dose should be taken twice per day before eating. Patients should be instructed to swallow each pill whole.

Lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg may interact with some drugs; therefore patients should be advised to report to their doctor the use of any other medications.

Patients should be counseled that antibacterial drugs including lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Patients should be advised to immediately report and seek care for diarrhea that does not improve. This may be a sign of *Clostridium difficile* associated diarrhea (see **WARNINGS**).

Patients should be advised to immediately report and seek care for any cardiovascular or neurological symptoms including palpitations, dizziness, seizures, and tetany as these

may be signs of hypomagnesemia (see **WARNINGS**).

Advise patients to report any symptoms associated with cutaneous or systemic lupus erythematosus (see **WARNINGS**).

Advise patients to report to their healthcare provider if they are taking rilpivirine-containing products or high-dose methotrexate (see **WARNINGS**).

## Laboratory Tests

Amoxicillin

Periodic assessment of renal, hepatic, and hematopoietic function should be made during prolonged therapy.

## Drug Interactions

No drug interaction studies have been conducted specifically with lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg. The following drug interactions are for the individual drug components: lansoprazole, amoxicillin, and clarithromycin. Therefore, the decision to adjust dosage should depend on the clinician's assessment of among other things, the cumulative or net effect of the drug components of lansoprazole delayed-release capsules USP, 30 mg, amoxicillin capsules USP, 500 mg, and clarithromycin tablets USP, 500 mg.

Lansoprazole

**Tables 5 and 6** include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with lansoprazole and instructions for preventing or managing them.

Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.

### **Table 5. Clinically Relevant Interactions Affecting Drugs Co-administered with Lansoprazole and Interactions with Diagnostics**

<b>Antiretrovirals</b>	
<i>Clinical Impact</i>	<p>The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.</p> <ul style="list-style-type: none"><li>• Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir, and nelfinavir) when used concomitantly with lansoprazole may reduce antiviral effect and promote the development of drug resistance.</li><li>• Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with lansoprazole may increase toxicity of the antiretroviral drugs.</li><li>• There are other antiretroviral drugs which do not result in clinically relevant interactions with lansoprazole.</li></ul>

<i>Intervention</i>	<p><u>Rilpivirine-containing products</u> Concomitant use with lansoprazole is contraindicated (see <b>CONTRAINDICATIONS</b>). See prescribing information.</p> <p><u>Atazanavir</u> See prescribing information for atazanavir for dosing information.</p> <p><u>Nelfinavir</u> Avoid concomitant use with lansoprazole. See prescribing information for nelfinavir.</p> <p><u>Saquinavir</u> See the prescribing information for saquinavir and monitor for potential saquinavir toxicities.</p> <p><u>Other antiretrovirals</u> See prescribing information.</p>
<b>Warfarin</b>	
<i>Clinical Impact</i>	Increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.
<i>Intervention</i>	Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin.
<b>Methotrexate</b>	
<i>Clinical Impact</i>	Concomitant use of PPIs with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted (see <b>WARNINGS</b> ).
<i>Intervention</i>	A temporary withdrawal of lansoprazole may be considered in some patients receiving high-dose methotrexate.
<b>Digoxin</b>	
<i>Clinical Impact</i>	Potential for increased exposure of digoxin.
<i>Intervention</i>	Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin.
<b>Theophylline</b>	
<i>Clinical Impact</i>	Increased clearance of theophylline (see <b>CLINICAL PHARMACOLOGY</b> ).
<i>Intervention</i>	Individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood concentrations.
<b>Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole)</b>	
<i>Clinical Impact</i>	Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.
	Mycophenolate mofetil (MMF): Co-administration of PPIs in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF

<i>Intervention</i>	solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving lansoprazole and MMF. Use lansoprazole with caution in transplant patients receiving MMF. See the prescribing information for other drugs dependent on gastric pH for absorption.
<b>Combination Therapy with Clarithromycin and Amoxicillin</b>	
<i>Clinical Impact</i>	Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions.
<i>Intervention</i>	<ul style="list-style-type: none"> <li>• See <b>CONTRAINDICATIONS, WARNINGS</b> and <b>PRECAUTIONS</b> in prescribing information for clarithromycin.</li> <li>• See Drug Interactions in prescribing information for amoxicillin.</li> </ul>
<b>Tacrolimus</b>	
<i>Clinical Impact</i>	Potentially increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.
<i>Intervention</i>	Monitor tacrolimus whole blood trough concentrations. Dose adjustment of tacrolimus may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus.
<b>Interactions with Investigations of Neuroendocrine Tumors</b>	
<i>Clinical Impact</i>	CgA levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors (see <b>WARNINGS, CLINICAL PHARMACOLOGY</b> ).
<i>Intervention</i>	Temporarily stop lansoprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.
<b>Interaction with Secretin Stimulation Test</b>	
<i>Clinical Impact</i>	Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.
<i>Intervention</i>	Temporarily stop lansoprazole treatment at least 28 days before assessing to allow gastrin levels to return to baseline (see <b>CLINICAL PHARMACOLOGY</b> ).
<b>False Positive Urine Tests for THC</b>	
<i>Clinical Impact</i>	There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.
<i>Intervention</i>	An alternative confirmatory method should be considered to verify positive results.

**Table 6. Clinically Relevant Interactions Affecting lansoprazole when Co-administered with Other Drugs**

<b>CYP2C19 OR CYP3A4 Inducers</b>	
<i>Clinical Impact</i>	Decreased exposure of lansoprazole when used concomitantly with strong inducers (see <b>CLINICAL PHARMACOLOGY</b> ).
<i>Intervention</i>	<u>St John's Wort, rifampin</u> Avoid concomitant use with lansoprazole. <u>Ritonavir-containing products</u> See prescribing information.
<b>CYP2C19 or CYP3A4 Inhibitors</b>	
<i>Clinical Impact</i>	Increased exposure of lansoprazole is expected when used concomitantly with strong inhibitors (see <b>CLINICAL PHARMACOLOGY</b> ).
<i>Intervention</i>	<u>Voriconazole</u> See prescribing information.
<b>Sucralfate</b>	
<i>Clinical Impact</i>	Decreased and delayed absorption of lansoprazole (see <b>CLINICAL PHARMACOLOGY</b> ).
<i>Intervention</i>	Take razole at least 30 minutes prior to sucralfate (see <b>CLINICAL PHARMACOLOGY</b> ).

Amoxicillin

*Probenecid*

Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin.

*Antibiotics*

Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with bactericidal effects of penicillin. This has been demonstrated *in vitro*; however, the clinical significance of this interaction is not well documented.

Amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

**Table 7. Clinically Significant Drug Interactions with Clarithromycin**

<b>Drugs That Are Affected By Clarithromycin</b>		
<b>Drug(s) with Pharmacokinetics Affected by Clarithromycin</b>	<b>Recommendation</b>	<b>Comments</b>
<b>Antiarrhythmics</b>		
Disopyramide Quinidine Dofetilide Amiodarone Sotalol	Not Recommended	<u>Disopyramide, Quinidine</u> There have been postmarketing reports of torsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide.

Procainamide		<p>Electrocardiograms should be monitored for QTc prolongation during coadministration of clarithromycin with these drugs (see <b>WARNINGS</b>).</p> <p>Serum concentrations of these medications should also be monitored. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with disopyramide and quinidine.</p> <p>There have been postmarketing reports of hypoglycemia with the concomitant administration of clarithromycin and disopyramide. Therefore, blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.</p>
Digoxin	Use With Caution	<p><u>Digoxin</u></p> <p>Digoxin is a substrate for P-glycoprotein (Pgp) and clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are coadministered inhibition of Pgp by clarithromycin may lead to increased exposure of digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Monitoring of serum digoxin concentrations should be considered, especially for patients with digoxin concentrations in the upper therapeutic range.</p>
<b>Oral Anticoagulants</b>		
Warfarin	Use With Caution	<p><u>Oral anticoagulants</u></p> <p>Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously (see <b>WARNINGS</b>).</p>
<b>Antiepileptics</b>		
Carbamazepine	Use With Caution	<p><u>Carbamazepine</u></p> <p>Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma</p>

		concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered. Increased serum concentrations of carbamazepine were observed in clinical trials with clarithromycin. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with carbamazepine.
<b>Antifungals</b>		
Itraconazole	Use With Caution	<u>Itraconazole</u> Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when administered concomitantly (see also Itraconazole under “Drugs That Affect Clarithromycin” in the table below). Clarithromycin may increase the plasma concentrations of itraconazole. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions.
Fluconazole	No Dose Adjustment	<u>Fluconazole</u> No dosage adjustment of clarithromycin is necessary when coadministered with fluconazole.
<b>Anti-Gout Agents</b>		
Colchicine (in patients with renal or hepatic impairment)	Contraindicated	<u>Colchicine</u> Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. The dose of colchicine should be reduced when coadministered with clarithromycin in patients with normal renal and hepatic function (see <b>CONTRAINDICATIONS, WARNINGS</b> ).
Colchicine (in patients with normal renal and hepatic function)	Use With Caution	
<b>Antipsychotics</b>		
Pimozide	Contraindicated	<u>Pimozide</u> (see <b>CONTRAINDICATIONS</b> ).
Quetiapine		<u>Quetiapine</u> Quetiapine is a substrate for CYP3A4, which is inhibited by clarithromycin. Coadministration with clarithromycin could result in increased quetiapine exposure and possible quetiapine related toxicities. There have

		been postmarketing reports of somnolence, orthostatic hypotension, altered state of consciousness, neuroleptic malignant syndrome, and QT prolongation during concomitant administration. Refer to quetiapine prescribing information for recommendations on dose reduction if coadministered with CYP3A4 inhibitors such as clarithromycin.
<b>Antispasmodics</b>		
Tolterodine (patients deficient in CYP2D6 activity)	Use With Caution	<u>Tolterodine</u> The primary route of metabolism for tolterodine is via CYP2D6. However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. Tolterodine 1 mg twice daily is recommended in patients deficient in CYP2D6 activity (poor metabolizers) when coadministered with clarithromycin.
<b>Antivirals</b>		
Atazanavir	Use With Caution	<u>Atazanavir</u> Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction (see Atazanavir under “Drugs That Affect Clarithromycin” in the table below).
Saquinavir (in patients with decreased renal function)		<u>Saquinavir</u> Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A and there is evidence of a bi-directional drug interaction (see Saquinavir under “Drugs That Affect Clarithromycin” in the table below).
Ritonavir Etravirine		<u>Ritonavir, Etravirine</u> (see Ritonavir and Etravirine under “Drugs That Affect Clarithromycin” in the table below).
Maraviroc		<u>Maraviroc</u> Clarithromycin may result in increases in maraviroc exposures by inhibition of CYP3A metabolism. See Selzentry <sup>®</sup> prescribing information for dose recommendation when given with strong CYP3A inhibitors such as clarithromycin.
Boceprevir (in patients	No Dose	<u>Boceprevir</u>

with normal renal function) Didanosine	Adjustment	Both clarithromycin and boceprevir are substrates and inhibitors of CYP3A, potentially leading to a bi-directional drug interaction when co-administered. No dose adjustments are necessary for patients with normal renal function (see Victrelis® prescribing information).
Zidovudine		Zidovudine: Simultaneous oral administration of clarithromycin immediate-release tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Administration of clarithromycin and zidovudine should be separated by at least two hours. The impact of coadministration of clarithromycin extended-release tablets or granules and zidovudine has not been evaluated.
<b>Calcium Channel Blockers</b>		
Verapamil	Use With Caution	<u>Verapamil</u> Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent verapamil (see <b>WARNINGS</b> ).
Amlodipine Diltiazem		<u>Amlodipine, Diltiazem</u> (see <b>WARNINGS</b> ).
Nifedipine		<u>Nifedipine</u> Nifedipine is a substrate for CYP3A. Clarithromycin and other macrolides are known to inhibit CYP3A. There is potential of CYP3A-mediated interaction between nifedipine and clarithromycin. Hypotension and peripheral edema were observed when clarithromycin was taken concomitantly with nifedipine (see <b>WARNINGS</b> ).
<b>Ergot Alkaloids</b>		
Ergotamine Dihydroergotamine	Contraindicated	<u>Ergotamine, Dihydroergotamine</u> Postmarketing reports indicate that co-administration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system (see <b>CONTRAINDICATIONS</b> ).
<b>Gastroprokinetic Agents</b>		

Cisapride	Contraindicated	Cisapride (see <b>CONTRAINDICATIONS</b> ).
<b>HMG-CoA Reductase Inhibitors</b>		
Lovastatin Simvastatin	Contraindicated	<u>Lovastatin, Simvastatin, Atorvastatin, Pravastatin, Fluvastatin</u> (see <b>CONTRAINDICATIONS, WARNINGS</b> ).
Atorvastatin Pravastatin	Use With Caution	
Fluvastatin	No Dose Adjustment	
<b>Hypoglycemic Agents</b>		
Nateglinide Pioglitazone Repaglinide Rosiglitazone	Use With Caution	<u>Nateglinide, Pioglitazone, Repaglinide, Rosiglitazone</u> (see <b>WARNINGS, ADVERSE REACTIONS</b> ).
Insulin		<u>Insulin</u> (see <b>WARNINGS, ADVERSE REACTIONS</b> ).
<b>Immunosuppressants</b>		
Cyclosporine	Use With Caution	<u>Cyclosporine</u> There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine.
Tacrolimus		<u>Tacrolimus</u> There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with tacrolimus.
<b>Phosphodiesterase Inhibitors</b>		
Sildenafil Tadalafil Vardenafil	Use With Caution	<u>Sildenafil, Tadalafil, Vardenafil</u> Each of these phosphodiesterase inhibitors is primarily metabolized by CYP3A, and CYP3A will be inhibited by concomitant administration of clarithromycin. Coadministration of clarithromycin with sildenafil, tadalafil, or vardenafil will result in increased exposure of these phosphodiesterase inhibitors. Coadministration of these phosphodiesterase inhibitors with clarithromycin is not recommended. Increased systemic exposure of these drugs may occur with clarithromycin; reduction of dosage for phosphodiesterase inhibitors should be considered (see their respective prescribing information).
<b>Proton Pump Inhibitors</b>		

Omeprazole	No Dose Adjustment	<u>Omeprazole</u> The mean 24 hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin as a result of increased omeprazole exposures (see also Omeprazole under “Drugs That Affect Clarithromycin” in the table below).
<b>Xanthine Derivatives</b>		
Theophylline	Use With Caution	<u>Theophylline</u> Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range.
<b>Triazolobenzodiazepines and Other Related Benzodiazepines</b>		
Midazolam	Use With Caution	<u>Midazolam</u> When oral midazolam is coadministered with clarithromycin, dose adjustments may be necessary and possible prolongation and intensity of effect should be anticipated (see <b>WARNINGS</b> ).
Alprazolam Triazolam		<u>Triazolam, Alprazolam</u> Caution and appropriate dose adjustments should be considered when triazolam or alprazolam is coadministered with clarithromycin. There have been postmarketing reports of drug interactions and central nervous system (CNS) effects (e.g., somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested. In postmarketing experience, erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines.
Temazepam Nitrazepam Lorazepam	No Dose Adjustment	<u>Temazepam, Nitrazepam, Lorazepam</u> For benzodiazepines which are not metabolized by CYP3A (e.g., temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is

		unlikely.
<b>Cytochrome P450 Inducers</b>		
Rifabutin	Use With Caution	<u>Rifabutin</u> Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis (see Rifabutin under “Drugs That Affect Clarithromycin” in the table below).
<b>Other Drugs Metabolized by CYP3A</b>		
Alfentanil Bromocriptine Cilostazol Methylprednisolone Vinblastine Phenobarbital St. John’s Wort	Use With Caution	There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with alfentanil, methylprednisolone, cilostazol, bromocriptine, vinblastine, phenobarbital, and St. John’s Wort.
<b>Other Drugs Metabolized by CYP450 Isoforms Other than CYP3A</b>		
Hexobarbital Phenytoin Valproate	Use With Caution	There have been postmarketing reports of interactions of clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.
<b>Drugs That Affect Clarithromycin</b>		
<b>Drug(s) that Affect the Pharmacokinetics of Clarithromycin</b>	<b>Recommendation</b>	<b>Comments</b>
<b>Antifungals</b>		
Itraconazole	Use With Caution	<u>Itraconazole</u> Itraconazole may increase the plasma concentrations of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged adverse reactions (see also Itraconazole under “Drugs That Are Affected By Clarithromycin” in the table above).
<b>Antivirals</b>		
Atazanavir	Use With Caution	<u>Atazanavir</u> When clarithromycin is coadministered with atazanavir, the dose of clarithromycin should be decreased by 50%. Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is coadministered with

		atazanavir, alternative antibacterial therapy should be considered for indications other than infections due to <i>Mycobacterium avium</i> complex. Doses of clarithromycin greater than 1000 mg per day should not be coadministered with protease inhibitors.
Ritonavir (in patients with decreased renal function)		<u>Ritonavir</u> Since concentrations of 14-OH clarithromycin are significantly reduced when clarithromycin is coadministered with ritonavir, alternative antibacterial therapy should be considered for indications other than infections due to <i>Mycobacterium avium</i> . Doses of clarithromycin greater than 1000 mg per day should not be coadministered with protease inhibitors.
Saquinavir (in patients with decreased renal function)		<u>Saquinavir</u> When saquinavir is coadministered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (refer to ritonavir above).
Etravirine		<u>Etravirine</u> Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OHclarithromycin has reduced activity against <i>Mycobacterium avium</i> complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.
Saquinavir (in patients with normal renal function) Ritonavir (in patients with normal renal function)	No Dose Adjustment	
<b>Proton Pump Inhibitors</b>		
Omeprazole	Use With Caution	<u>Omeprazole</u> Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.
<b>Miscellaneous Cytochrome P450 Inducers</b>		
Efavirenz Nevirapine Rifampicin Rifabutin	Use With Caution	Inducers of CYP3A enzymes, such as efavirenz, nevirapine, rifampicin, rifabutin, and rifapentine will increase the metabolism of

Rifapentine	clarithromycin, thus decreasing plasma concentrations of clarithromycin, while increasing those of 14-OH-clarithromycin. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers. Alternative antibacterial treatment should be considered when treating patients receiving inducers of CYP3A. There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with rifabutin (see Rifabutin under “Drugs That Are Affected By Clarithromycin” in the table above).
-------------	--

### **Drug/Laboratory Test Interactions**

High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST, Benedict’s Solution or Fehling’s Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX) be used.

Following administration of ampicillin or amoxicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### Lansoprazole

In two 24-month carcinogenicity studies, Sprague-Dawley rats were treated with oral lansoprazole at doses of 5 to 150 mg/kg/day, about 0.5 to 20 times the recommended human dose of 60 mg/day, based on body surface area (BSA). Lansoprazole produced dose-related gastric enterochromaffin-like (ECL) cell hyperplasia and ECL cell carcinoids in both male and female rats. The incidences of intestinal metaplasia of the gastric epithelium were also increased in both sexes. In male rats, lansoprazole produced a dose-related increase in the incidence of testicular interstitial cell adenomas at doses two to 20 times the recommended human dose of 60 mg/day based on BSA.

In a 24-month carcinogenicity study, CD-1 mice were treated with oral lansoprazole at doses of 15 to 600 mg/kg/day (one to 40 times the recommended human dose of 60 mg/day based on BSA comparisons). Lansoprazole produced a dose-related increased incidence of gastric ECL cell hyperplasia. The incidence of liver tumors (hepatocellular adenoma plus carcinoma) was increased in male mice (at doses 20 to 40 times the recommended human dose of 60 mg/day based on BSA) and in female mice (treated at doses ten to 40 times the recommended human dose based on BSA). Lansoprazole treatment produced adenoma of rete testis in male mice receiving doses five to 40 times

the recommended human dose of 60 mg/day based on BSA.

A 26 week p53 (+/-) transgenic mouse carcinogenicity study was not positive.

Lansoprazole was positive in the Ames test and the *in vitro* human lymphocyte chromosomal aberration assay. Lansoprazole was not genotoxic in the *ex vivo* rat hepatocyte unscheduled DNA synthesis (UDS) test, the *in vivo* mouse micronucleus test, or the rat bone marrow cell chromosomal aberration test.

Lansoprazole at oral doses up to 150 mg/kg/day (20 times the recommended human dose of 60 mg/day based on BSA) was found to have no effect on fertility and reproductive performance of male and female rats.

### Amoxicillin

Long-term studies in animals have not been performed to evaluate the mutagenic or carcinogenic potential of amoxicillin alone. A 4:1 mixture of amoxicillin and potassium clavulanate was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay. The amoxicillin/potassium clavulanate mixture was also negative in the mouse micronucleus test, and in the dominant lethal assay in mice, but was weakly positive in the mouse lymphoma assay. In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg, approximately three times the human dose based on BSA comparisons.

### Clarithromycin

The following *in vitro* mutagenicity tests have been conducted with clarithromycin:

*Salmonella*/Mammalian Microsomes Test

Bacterial Induced Mutation Frequency Test

*In Vitro* Chromosome Aberration Test

Rat Hepatocyte DNA Synthesis Assay

Mouse Lymphoma Assay

Mouse Dominant Lethal Study

Mouse Micronucleus Test

All tests had negative results except the *In Vitro* Chromosome Aberration Test which was weakly positive in one test and negative in another.

In addition, a Bacterial Reverse-Mutation Test (Ames Test) has been performed on clarithromycin metabolites with negative results.

Fertility and reproduction studies have shown that daily doses of up to 160 mg/kg/day (1.3 times the recommended maximum human dose based on mg/m<sup>2</sup>) to male and female rats caused no adverse effects on the estrous cycle, fertility, parturition, or number and viability of offspring. Plasma levels in rats after 150 mg/kg/day were two times the human serum levels.

In the 150 mg/kg/day monkey studies, plasma levels were three times the human serum levels. When given orally at 150 mg/kg/day (2.4 times the recommended maximum human dose based on mg/m<sup>2</sup>), clarithromycin was shown to produce embryonic loss in

monkeys. This effect has been attributed to marked maternal toxicity of the drug at this high dose.

In rabbits, *in utero* fetal loss occurred at an intravenous dose of 33 mg/m<sup>2</sup>, which is 17 times less than the maximum proposed human oral daily dose of 618 mg/m<sup>2</sup>.

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of clarithromycin.

## **Pregnancy**

### ***Teratogenic Effects***

#### *Pregnancy Category C*

Category C is based on the pregnancy category for clarithromycin.

There are no adequate and well-controlled studies of lansoprazole, clarithromycin or amoxicillin (used separately or together) in pregnant women. Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus and there is no appropriate alternative therapy (see **WARNINGS**).

#### Lansoprazole

No adverse effects on embryo-fetal development occurred in studies performed in pregnant rats at oral lansoprazole doses up to 150 mg/kg/day (40 times the recommended human dose [30 mg/day] based on body surface area) administered during organogenesis and pregnant rabbits at oral lansoprazole doses up to 30 mg/kg/day (16 times the recommended human dose based on body surface area) administered during organogenesis.

A pre- and postnatal developmental toxicity study in rats with additional endpoints to evaluate bone development was performed with lansoprazole at oral doses of 10 to 100 mg/kg/day (0.7 to 6.4 times the maximum recommended human lansoprazole dose of 30 mg based on AUC [area under the plasma concentration-time curve]) administered during organogenesis through lactation. Maternal effects observed at 100 mg/kg/day (6.4 times the maximum recommended human lansoprazole dose of 30 mg based on AUC) included increased gestation period, decreased body weight gain during gestation, and decreased food consumption. The number of stillbirths was increased at this dose, which may have been secondary to maternal toxicity. Body weight of pups was reduced at 100 mg/kg/day starting on postnatal Day 11. Femur weight, femur length, and crown-rump length were reduced at 100 mg/kg/day on postnatal Day 21. Femur weight was still decreased in the 100 mg/kg/day group at age 17 to 18 weeks. Growth plate thickness was decreased in the 100 mg/kg/day males on postnatal Day 21, and was increased in the 30 and 100 mg/kg/day males at age 17 to 18 weeks. The effects on bone parameters were associated with reduction in body weight gain.

#### Amoxicillin

Reproduction studies with amoxicillin have been performed in mice and rats at doses up to ten times the human dose and revealed no evidence of impaired fertility or harm to the fetus.

## Clarithromycin

Four teratogenicity studies in rats with clarithromycin (three with oral doses and one with intravenous doses up to 160 mg/kg/day administered during the period of major organogenesis) and two in rabbits at oral doses up to 125 mg/kg/day (approximately two times the recommended maximum human dose based on mg/m<sup>2</sup>) or intravenous doses of 30 mg/kg/day administered during gestation days six to 18 failed to demonstrate any teratogenicity from clarithromycin. Two additional oral studies in a different rat strain at similar doses and similar conditions demonstrated a low incidence of cardiovascular anomalies at doses of 150 mg/kg/day administered during gestation days six to 15. Plasma levels after 150 mg/kg/day were two times the human serum levels. Four studies in mice revealed a variable incidence of cleft palate following oral doses of 1000 mg/kg/day (two and four times the recommended maximum human dose based on mg/m<sup>2</sup>, respectively) during gestation days six to 15. Cleft palate was also seen at 500 mg/kg/day. The 1000 mg/kg/day exposure resulted in plasma levels 17 times the human serum levels. In monkeys, an oral dose of 70 mg/kg/day (an approximate equidose of the recommended maximum human dose based on mg/m<sup>2</sup>) produced fetal growth retardation at plasma levels that were two times the human serum levels.

## **Labor and Delivery**

Oral ampicillin-class antibiotics are poorly absorbed during labor. Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions, but moderately increased the height and duration of contractions. However, it is not known whether use of these drugs in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.

## **Nursing Mothers**

Lansoprazole and its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from lansoprazole, amoxicillin and clarithromycin, and the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue lansoprazole, amoxicillin and clarithromycin, taking into account the importance of the therapy to the mother.

Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants. Caution should be exercised when amoxicillin is administered to a nursing woman.

Clarithromycin and its active metabolite 14-hydroxy clarithromycin are excreted in human milk. Serum and milk samples were obtained after three days of treatment, at steady state, from one published study of 12 lactating women who were taking clarithromycin 250 mg orally twice daily. Based on the limited data from this study, and assuming milk consumption of 150 mL/kg/day, an exclusively human milk-fed infant would receive an estimated average of 136 mcg/kg/day of clarithromycin and its active metabolite, with this maternal dosage regimen. This is less than 2% of the maternal weight-adjusted dose (7.8 mg/kg/day, based on the average maternal weight of 64 kg),

and less than 1% of the pediatric dose (15 mg/kg/day) for children greater than six months of age.

A prospective observational study of 55 breastfed infants of mothers taking a macrolide antibiotic (six were exposed to clarithromycin) were compared to 36 breastfed infants of mothers taking amoxicillin. Adverse reactions were comparable in both groups. Adverse reactions occurred in 12.7% of infants exposed to macrolides and included rash, diarrhea, loss of appetite, and somnolence.

Caution should be exercised when clarithromycin is administered to nursing women. The development and health benefits of human milk feeding should be considered along with the mother's clinical need for clarithromycin and any potential adverse effects on the human milk-fed child from the drug or from the underlying maternal condition.

## **Pediatric Use**

The safety and effectiveness of lansoprazole, amoxicillin and clarithromycin in pediatric patients infected with *H. pylori* have not been established.

## **Juvenile Animal Toxicity Data**

In a juvenile rat study, adverse effects on bone growth and development and heart valves were observed at lansoprazole doses higher than the maximum recommended equivalent human dose.

An eight-week oral toxicity study with a four-week recovery phase was conducted in juvenile rats, with lansoprazole administered from postnatal Day 7 (age equivalent to neonatal humans) through 62 (age equivalent to approximately 14 years in humans) at doses of 40 to 500 mg/kg/day (about 1.2 to 12 times the daily pediatric dose of 15 mg in children age one to 11 years weighing 30 kg or less, based on AUC).

Heart valve thickening occurred at a dose of 500 mg/kg/day (approximately 12 times the daily dose of 15 mg in pediatric patients age one to 11 years weighing 30 kg or less, based on AUC). Heart valve thickening was not observed at the next lower dose (250 mg/kg/day) and below. The findings trended towards reversibility after a four-week drug-free recovery period. The relevance of heart valve thickening in this study to pediatric patients less than approximately 12 years of age is unknown. These findings are not relevant for patients 12 years of age and older. No effects on heart valves were observed in a 13-week intravenous toxicity study of lansoprazole in adolescent rats (approximately 12 years human age equivalence) at systemic exposures similar to those achieved in the eight-week oral toxicity study in juvenile (neonatal) rats.

In the eight-week oral toxicity study, doses equal to or greater than 100 mg/kg/day (about 2.5 times the daily pediatric dose of 15 mg in children age one to 11 years weighing 30 kg or less, based on AUC) produced delayed growth, with impairment of weight gain observed as early as postnatal Day 10 (age equivalent to neonatal humans). At the end of treatment, the signs of impaired growth at 100 mg/kg/day and higher included reductions in body weight (14% to 44% compared to controls), absolute weight of multiple organs, femur weight, femur length, and crown-rump length. Femoral growth plate thickness was reduced only in males and only at the 500 mg/kg/day dose. The effects related to delayed growth persisted through the end of the 4-week recovery period. Longer term data were not collected.

## **Geriatric Use**

Elderly patients may suffer from asymptomatic renal and hepatic dysfunction. Care should be taken when administering Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg to this patient population.

An analysis of clinical studies of amoxicillin was conducted to determine whether subjects aged 65 and over respond differently from younger subjects. These analyses have not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.

Amoxicillin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

In a steady-state study in which healthy elderly subjects (age 65 to 81 years old) were given 500 mg of clarithromycin every 12 hours, the maximum serum concentrations and area under the curves of clarithromycin and 14-OH-clarithromycin were increased compared to those achieved in healthy young adults. These changes in pharmacokinetics parallel known age-related decreases in renal function. In clinical trials of clarithromycin, elderly patients did not have an increased incidence of adverse events when compared to younger patients. Dosage adjustment should be considered in elderly patients with severe renal impairment. Elderly patients may be more susceptible to development of *torsades de pointes* arrhythmias than younger patients (see **WARNINGS** and **PRECAUTIONS**).

Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine) involved elderly patients 65 years of age or older (see **WARNINGS**).

## ADVERSE REACTIONS

### Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The most common adverse reactions ( $\geq 3\%$ ) reported in clinical trials when all three components of this therapy were given concomitantly for 14 days are listed in **Table 8**.

**Table 8: Adverse Reactions Most Frequently Reported in Clinical Trials ( $\geq 3\%$ )**

Adverse Reaction	Triple Therapy
	n=138 (%)
Diarrhea	7
Headache	6
Taste Perversion	5

The additional adverse reactions which were reported as possibly or probably related to treatment (less than 3%) in clinical trials when all three components of this therapy were given concomitantly are listed below and divided by body system:

*Body as a Whole* – abdominal pain

*Digestive System* – dark stools, dry mouth/thirst, glossitis, rectal itching, nausea, oral moniliasis, stomatitis, tongue discoloration, tongue disorder, vomiting

*Musculoskeletal System* – myalgia

*Nervous System* – confusion, dizziness

*Respiratory System* – respiratory disorders

*Skin and Appendages* – skin reactions

*Urogenital System* – vaginitis, vaginal moniliasis

There were no statistically significant differences in the frequency of reported adverse events between the 10- and 14-day triple therapy regimens.

## **Lansoprazole**

The following adverse reactions from the labeling for lansoprazole are provided for information.

Worldwide, over 10,000 patients have been treated with lansoprazole in Phase 2 or Phase 3 clinical trials involving various dosages and durations of treatment. In general, lansoprazole treatment has been well-tolerated in both short-term and long-term trials.

### ***Incidence in Clinical Trials***

The following adverse events were reported by the treating physician to have a possible or probable relationship to drug in 1% or more of lansoprazole-treated patients and occurred at a greater rate in lansoprazole-treated patients than placebo-treated patients:

**Table 9: Incidence of Possibly or Probably Treatment-Related Adverse Reactions in Short-Term, Placebo-Controlled Lansoprazole Studies**

<b>Body System/Adverse Event</b>	<b>Lansoprazole (N= 2768) %</b>	<b>Placebo (N= 1023) %</b>
<b>Body as a Whole</b>		
Abdominal Pain	2.1	1.2
<b>Digestive System</b>		
Constipation	1	0.4
Diarrhea	3.8	2.3
Nausea	1.3	1.2

Headache was also seen at greater than 1% incidence but was more common on placebo. The incidence of diarrhea was similar between patients who received placebo and patients who received 30 mg of lansoprazole, but higher in the patients who

received 60 mg of lansoprazole (2.9%, 4.2%, and 7.4%, respectively).

The most commonly reported possibly or probably treatment-related adverse event during maintenance therapy was diarrhea.

Additional adverse experiences occurring in less than 1% of patients or subjects who received lansoprazole in domestic trials are shown below.

*Body as a Whole* – abdomen enlarged, allergic reaction, asthenia, back pain, candidiasis, carcinoma, chest pain (not otherwise specified), chills, edema, fever, flu syndrome, halitosis, infection (not otherwise specified), malaise, neck pain, neck rigidity, pain, pelvic pain

*Cardiovascular System* – angina, arrhythmia, bradycardia, cerebrovascular accident/cerebral infarction, hypertension/hypotension, migraine, myocardial infarction, palpitations, shock (circulatory failure), syncope, tachycardia, vasodilation

*Digestive System* – abnormal stools, anorexia, bezoar, cardiospasm, cholelithiasis, colitis, dry mouth, dyspepsia, dysphagia, enteritis, eructation, esophageal stenosis, esophageal ulcer, esophagitis, fecal discoloration, flatulence, gastric nodules/fundic gland polyps, gastritis, gastroenteritis, gastrointestinal anomaly, gastrointestinal disorder, gastrointestinal hemorrhage, glossitis, gum hemorrhage, hematemesis, increased appetite, increased salivation, melena, mouth ulceration, nausea and vomiting, nausea and vomiting and diarrhea, gastrointestinal moniliasis, rectal disorder, rectal hemorrhage, stomatitis, tenesmus, thirst, tongue disorder, ulcerative colitis, ulcerative stomatitis

*Endocrine System* – diabetes mellitus, goiter, hypothyroidism

*Hemic and Lymphatic System* – anemia, hemolysis, lymphadenopathy

*Metabolism and Nutritional Disorders* – avitaminosis, gout, dehydration, hyperglycemia/hypoglycemia, peripheral edema, weight gain/loss

*Musculoskeletal System* – arthralgia, arthritis, bone disorder, joint disorder, leg cramps, musculoskeletal pain, myalgia, myasthenia, ptosis, synovitis

*Nervous System* – abnormal dreams, agitation, amnesia, anxiety, apathy, confusion, convulsion, dementia, depersonalization, depression, diplopia, dizziness, emotional lability, hallucinations, hemiplegia, hostility aggravated, hyperkinesia, hypertonia, hypesthesia, insomnia, libido decreased/increased, nervousness, neurosis, paresthesia, sleep disorder, somnolence, thinking abnormality, tremor, vertigo

*Respiratory System* – asthma, bronchitis, cough increased, dyspnea, epistaxis, hemoptysis, hiccup, laryngeal neoplasia, lung fibrosis, pharyngitis, pleural disorder, pneumonia, respiratory disorder, upper respiratory inflammation/infection, rhinitis, sinusitis, stridor

*Skin and Appendages* – acne, alopecia, contact dermatitis, dry skin, fixed eruption, hair disorder, maculopapular rash, nail disorder, pruritus, rash, skin carcinoma, skin disorder, sweating, urticaria

*Special Senses* – abnormal vision, amblyopia, blepharitis, blurred vision, cataract, conjunctivitis, deafness, dry eyes, ear/eye disorder, eye pain, glaucoma, otitis media, parosmia, photophobia, retinal degeneration/disorder, taste loss, taste perversion, tinnitus, visual field defect

*Urogenital System* – abnormal menses, breast enlargement, breast pain, breast tenderness, dysmenorrhea, dysuria, gynecomastia, impotence, kidney calculus, kidney pain, leukorrhea, menorrhagia, menstrual disorder, penis disorder, polyuria, testis disorder, urethral pain, urinary frequency, urinary retention, urinary tract infection, urinary urgency, urination impaired, vaginitis

## **Post-Marketing**

Additional adverse experiences have been reported since lansoprazole has been marketed. The majority of these cases are foreign-sourced and a relationship to lansoprazole has not been established. Because these events were reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events are listed below by COSTART body system.

*Body as a Whole* – anaphylactic/anaphylactoid reactions, systemic lupus erythematosus

*Digestive System* – hepatotoxicity, pancreatitis, vomiting

*Hemic and Lymphatic System* – agranulocytosis, aplastic anemia, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, and thrombotic thrombocytopenic purpura

*Infections and Infestations* – *Clostridium difficile* associated diarrhea

*Metabolism and Nutritional Disorders* – hypomagnesemia

*Musculoskeletal System* – bone fracture, myositis

*Skin and Appendages* – severe dermatologic reactions including erythema multiforme, Stevens - Johnson Syndrome, toxic epidermal necrolysis, (some-fatal), cutaneous lupus erythematosus

*Special Senses* – speech disorder

*Urogenital System* – interstitial nephritis, urinary retention

## **Amoxicillin**

The following adverse reactions from the labeling for amoxicillin are provided for information:

The most common adverse reactions (>1%) observed in clinical trials of amoxicillin capsules were diarrhea, rash, vomiting and nausea.

The most frequently reported adverse events for patients who received triple therapy (amoxicillin/clarithromycin/lansoprazole) were diarrhea (7%), headache (6%), and taste perversion (5%).

*Infections and Infestations* – *Mucocutaneous candidiasis*

*Gastrointestinal* – Black hairy tongue, and hemorrhagic/pseudomembranous colitis.

Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment (see **WARNINGS**).

*Hypersensitivity Reactions* – Anaphylaxis (see **WARNINGS**), serum sickness-like reactions, erythematous maculopapular rashes, erythema multiforme, Stevens - Johnson Syndrome, exfoliative dermatitis, toxic epidermal necrolysis, acute generalized

exanthematous pustulosis, hypersensitivity vasculitis and urticaria have been reported.

*Liver* – A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.

*Renal* – Crystalluria has also been reported (see **OVERDOSAGE**).

*Hemic and Lymphatic Systems* – Anemia, including hemolytic anemia, thrombocytopenia, thrombocytopenic purpura, eosinophilia, leukopenia and agranulocytosis have been reported. These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena.

*Central Nervous System* – Reversible hyperactivity, agitation, anxiety, insomnia, confusion, behavioral changes, and/or dizziness have been reported.

*Miscellaneous* – Tooth discoloration (brown, yellow, or gray staining) has been reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.

## **Clarithromycin**

The following adverse reactions from the labeling for clarithromycin are provided for information:

The most frequent and common adverse reactions related to clarithromycin therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting, and dysgeusia. These adverse reactions are consistent with the known safety profile of macrolide antibiotics.

There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.

### **Adverse Reactions Observed During Clinical Trials of Clarithromycin**

The following adverse reactions were observed in clinical trials with clarithromycin at a rate greater than or equal to 1%:

*Gastrointestinal Disorders* – Diarrhea, vomiting, dyspepsia, nausea, abdominal pain

*Hepatobiliary Disorders* – Liver function test abnormal

*Immune System Disorders* – Anaphylactoid reaction

*Infections and Infestations* – *Candidiasis*

*Nervous System Disorders* – Dysgeusia, headache

*Psychiatric Disorders* – Insomnia

*Skin and Subcutaneous Tissue Disorders* – Rash

### **Other Adverse Reactions Observed During Clinical Trials of Clarithromycin**

The following adverse reactions were observed in clinical trials with clarithromycin at a rate less than 1%:

*Blood and Lymphatic System Disorders* – Leukopenia, neutropenia, thrombocythemia, eosinophilia

*Cardiac Disorders* – Electrocardiogram QT prolonged, cardiac arrest, atrial fibrillation, extrasystoles, palpitations

*Ear and Labyrinth Disorders* – Vertigo, tinnitus, hearing impaired

*Gastrointestinal Disorders* – Stomatitis, glossitis, esophagitis, gastroesophageal reflux disease, gastritis, proctalgia, abdominal distention, constipation, dry mouth, eructation, flatulence

*General Disorders and Administration Site Conditions* – Malaise, pyrexia, asthma, chest pain, chills, fatigue

*Hepatobiliary Disorders* – Cholestasis, hepatitis

*Immune System Disorders* – Hypersensitivity

*Infections and Infestations* – Cellulitis, gastroenteritis, infection, vaginal infection

*Investigations* – Blood bilirubin increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, albumin globulin ratio abnormal

*Metabolism and Nutrition Disorders* – Anorexia, decreased appetite

*Musculoskeletal and Connective Tissue Disorders* – Myalgia, muscle spasms, nuchal rigidity

*Nervous System Disorders* – Dizziness, tremor, loss of consciousness, dyskinesia, somnolence

*Psychiatric Disorders* – Anxiety, nervousness

*Renal and Urinary Disorders* – Blood creatinine increased, blood urea increased

*Respiratory, Thoracic and Mediastinal Disorders* – Asthma, epistaxis, pulmonary embolism

*Skin and Subcutaneous Tissue Disorders* – Urticaria, dermatitis bullus, pruritus, hyperhidrosis, rash maculopapular

The following adverse reactions have been identified during post approval use of clarithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

*Blood and Lymphatic System Disorders* – Thrombocytopenia, agranulocytosis

*Cardiac Disorders* – Torsades de pointes, ventricular tachycardia, ventricular arrhythmia

*Ear and Labyrinth Disorders* – Deafness was reported chiefly in elderly women and was usually reversible.

*Gastrointestinal Disorders* – Pancreatitis acute, tongue discoloration, tooth discoloration was reported and was usually reversible with professional cleaning upon discontinuation of the drug.

*Hepatobiliary Disorders* – Hepatic failure, jaundice hepatocellular. Adverse reactions related to hepatic dysfunction have been reported with clarithromycin (see **WARNINGS, Hepatotoxicity**)

*Immune System Disorders* – Anaphylactic reaction

*Infections and Infestations* – Pseudomembranous colitis

*Investigations* – Prothrombin time prolonged, white blood cell count decreased, international normalized ratio increased. Abnormal urine color has been reported, associated with hepatic failure.

*Metabolism and Nutrition Disorders* – Hypoglycemia has been reported in patients taking oral hypoglycemic agents or insulin.

*Musculoskeletal and Connective Tissue Disorders* – Myopathy, rhabdomyolysis was reported and in some of the reports, clarithromycin was administered concomitantly with statins, fibrates, colchicines or allopurinol (see **CONTRAINDICATIONS** and **WARNINGS**).

*Nervous System Disorders* – Convulsion, ageusia, parosmia, anosmia, paresthesia

*Psychiatric Disorders* – Psychotic disorder, confusional state, depersonalization, depression, disorientation, manic behavior, hallucination, abnormal behavior, abnormal dreams. These disorders usually resolve upon discontinuation of the drug.

There are no data on the effect of clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.

*Renal and Urinary Disorders* – Nephritis interstitial, renal failure

*Skin and Subcutaneous Tissue Disorders* – Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), Henoch-Schonlein purpura, acne

*Vascular Disorders* – Hemorrhage

There have been reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients (see **WARNINGS** and **PRECAUTIONS**).

## **Laboratory Values**

### ***Lansoprazole***

The following changes in laboratory parameters in patients who received lansoprazole were reported as adverse reactions:

Abnormal liver function tests, increased SGOT (AST), increased SGPT (ALT), increased creatinine, increased alkaline phosphatase, increased globulins, increased GGTP, increased/decreased/abnormal WBC, abnormal AG ratio, abnormal RBC, bilirubinemia, blood potassium increased, blood urea increased, crystal urine present, eosinophilia, hemoglobin decreased, hyperlipemia, increased/decreased electrolytes, increased/decreased cholesterol, increased glucocorticoids, increased LDH, increased/decreased/abnormal platelets, increased gastrin levels and positive fecal occult blood. Urine abnormalities such as albuminuria, glycosuria, and hematuria were also reported.

In the placebo-controlled studies, when SGOT (AST) and SGPT (ALT) were evaluated,

0.4% (4/978) and 0.4% (11/2677) patients, who received placebo and lansoprazole, respectively, had enzyme elevations greater than three times the upper limit of normal range at the final treatment visit. None of these patients who received lansoprazole reported jaundice at any time during the study.

## **OVERDOSAGE**

In case of an overdose, patients should contact a physician, poison control center, or emergency room. There is neither a pharmacologic basis nor data suggesting an increased toxicity of the combination compared to individual components.

In the event of over-exposure, treatment should be symptomatic and supportive.

If over-exposure occurs, call your poison control center at 1-800-222-1222 for current information on the management of poisoning or over-exposure.

## **Amoxicillin**

In case of amoxicillin overdose, discontinue medication, treat symptomatically and institute supportive measures as needed. If the overdose is very recent and there is no contraindication, an attempt at emesis or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying<sup>2</sup>.

Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdose with amoxicillin.

Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdose in adult and pediatric patients. In case of overdose, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin can be removed from circulation by hemodialysis.

## **Clarithromycin**

Overdose of clarithromycin can cause gastrointestinal symptoms such as abdominal pain, vomiting, nausea, and diarrhea.

Adverse reactions accompanying overdose should be treated by the prompt elimination of unabsorbed drug and supportive measures. As with other macrolides, clarithromycin serum concentrations are not expected to be appreciably affected by hemodialysis or peritoneal dialysis.

## **Lansoprazole**

Lansoprazole is not removed from the circulation by hemodialysis. In one reported overdose, a patient consumed 600 mg of lansoprazole with no adverse reaction. Oral lansoprazole doses up to 5000 mg/kg in rats (approximately 650 times the recommended human dose of 60 mg/day based on BSA) and in mice (about 338 times the recommended human dose of 60 mg/day based on BSA) did not produce deaths or

any clinical signs.

## **DOSAGE AND ADMINISTRATION**

### ***H. pylori* Eradication to Reduce the Risk of Duodenal Ulcer Recurrence**

The recommended adult oral dose is 30 mg lansoprazole, 1 g amoxicillin, and 500 mg clarithromycin administered together twice daily (morning and evening) for 10 or 14 days (see **INDICATIONS AND USAGE**).

Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg is not recommended in patients with creatinine clearance less than 30 mL/min.

## **HOW SUPPLIED**

Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg are supplied in boxes of 14 daily administration cards, each card containing:

Lansoprazole Delayed-Release Capsules USP, 30 mg: Two white hypromellose capsules with GG638 black imprint on cap and body of the capsule, containing white to off-white pellets.

Amoxicillin Capsules USP, 500 mg: Four yellow, opaque, hard gelatin amoxicillin 500 mg capsules, USP, imprinted AMOX 500 on one side and GG 849 on the other side.

Clarithromycin Tablets USP, 500 mg: Two white oval film-coated tablets, debossed GG C9 on one side and plain on the reverse side.

NDC 0781-4054-42 Carton containing 14 daily administration cards

NDC 0781-4054-32 Daily administration card

Store between 20°C and 25°C (68°F and 77°F) [see USP Controlled Room Temperature]. Protect from light and moisture.

## **REFERENCES**

1. CLSI. Methods for Antimicrobial Dilution and Disk Diffusion Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria – 2<sup>nd</sup> edition. CLSI document M45-A2, 2010.
2. Swanson Bierman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. Vet Hum Toxicol. 1988; 30: 66-67.

*triple therapy* Lansoprazole Delayed-Release Capsules USP, 30 mg, Amoxicillin Capsules USP, 500 mg, and Clarithromycin Tablets USP, 500 mg is packaged in Austria by Sandoz GmbH for Sandoz Inc., Princeton, NJ 08540

Lansoprazole Delayed-Release Capsules USP, 30 mg, Manufactured by Sandoz Private Ltd., India

Amoxicillin Capsules USP, 500 mg, Manufactured by Sandoz GmbH, Kundl, Austria

Clarithromycin Tablets USP, 500 mg, Manufactured by Sandoz Inc., Colorado, USA or Sandoz S.R.L., Targu Mures, Romania"

46233128

Revised: March 2019

## Triple Therapy Carton



NDC 0781-4054-42

*triple therapy*

Lansoprazole Delayed-Release Capsules, USP

Amoxicillin Capsules, USP

Clarithromycin Tablets, USP

30mg/500mg/500mg

EACH DAILY PATIENT CARD CONTAINS:

2 Lansoprazole Delayed-Release Capsules USP, 30 mg

4 Amoxicillin Capsules USP, 500 mg

2 Clarithromycin Tablets USP, 500 mg

Rx Only

14 DAILY PATIENT CARDS

SANDOZ - A Novartis Division

## LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

lansoprazole, amoxicillin and clarithromycin kit

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:0781-4054
---------------------	-------------------------	---------------------------	---------------

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0781-4054-42	14 in 1 CARTON	03/04/2014	
1	NDC:0781-4054-32	1 in 1 BLISTER PACK; Type 0: Not a Combination Product		

### Quantity of Parts

Part #	Package Quantity	Total Product Quantity
Part 1		2
Part 2		4
Part 3		2

### Part 1 of 3

## LANSOPRAZOLE

lansoprazole capsule, delayed release

### Product Information

<b>Route of Administration</b>	ORAL
--------------------------------	------

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
LANSOPRAZOLE (UNII: 0K5C5T2QPG) (LANSOPRAZOLE - UNII:0K5C5T2QPG)	LANSOPRAZOLE	30 mg

## Inactive Ingredients

Ingredient Name	Strength
CARRAGEENAN (UNII: 5C69YCD2YJ)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)	
MAGNESIUM CARBONATE (UNII: 0E53J927NA)	
METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A (UNII: NX76LV5T8J)	
POLYETHYLENE GLYCOL 400 (UNII: B697894SGQ)	
POTASSIUM CHLORIDE (UNII: 660YQ98I10)	
SUCROSE (UNII: C151H8M554)	
TALC (UNII: 7SEV7J4R1U)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	
CARNAUBA WAX (UNII: R12CBM0EIZ)	
FD&C BLUE NO. 2 (UNII: L06K8R7DQK)	
FERRIC OXIDE RED (UNII: 1K09F3G675)	
SHELLAC (UNII: 46N107B71O)	
FERRIC OXIDE YELLOW (UNII: EX438O2MRT)	
GLYCERYL 1-OLEATE (UNII: D3AEF6S35P)	
STARCH, CORN (UNII: O8232NY3SJ)	

## Product Characteristics

Color	WHITE	Score	no score
Shape	CAPSULE	Size	16mm
Flavor		Imprint Code	GG638
Contains			

## Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA202588	03/04/2014	

## Part 2 of 3

### AMOXICILLIN

amoxicillin capsule

## Product Information

Route of Administration	ORAL
-------------------------	------

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>AMOXICILLIN</b> (UNII: 804826J2HU) (AMOXICILLIN ANHYDROUS - UNII:9EM05410Q9)	AMOXICILLIN ANHYDROUS	500 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>FERROSO FERRIC OXIDE</b> (UNII: XM0M87F357)	
<b>MICROCRYSTALLINE CELLULOSE</b> (UNII: OP1R32D61U)	
<b>GELATIN, UNSPECIFIED</b> (UNII: 2G86QN327L)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6130)	
<b>TITANIUM DIOXIDE</b> (UNII: 15FIX9V2JP)	
<b>FERRIC OXIDE YELLOW</b> (UNII: EX438O2MRT)	
<b>SHELLAC</b> (UNII: 46N107B71O)	
<b>ISOPROPYL ALCOHOL</b> (UNII: ND2M416302)	
<b>BUTYL ALCOHOL</b> (UNII: 8PJ61P6TS3)	
<b>PROPYLENE GLYCOL</b> (UNII: 6DC9Q167V3)	
<b>AMMONIA</b> (UNII: 5138Q19F1X)	
<b>POTASSIUM HYDROXIDE</b> (UNII: WZH3C48M4T)	
<b>ALCOHOL</b> (UNII: 3K9958V90M)	

### Product Characteristics

<b>Color</b>	YELLOW	<b>Score</b>	no score
<b>Shape</b>	CAPSULE	<b>Size</b>	22mm
<b>Flavor</b>		<b>Imprint Code</b>	AMOX500;GG849
<b>Contains</b>			

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA202588	03/04/2014	

### Part 3 of 3

### CLARITHROMYCIN

clarithromycin tablet, film coated

### Product Information

<b>Route of Administration</b>	ORAL
--------------------------------	------

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
-----------------	-------------------	----------

**CLARITHROMYCIN** (UNII: H1250JIK0A) (CLARITHROMYCIN - UNII:H1250JIK0A) | CLARITHROMYCIN | 500 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>CROSCARMELOSE SODIUM</b> (UNII: M28OL1HH48)	
<b>HYPROMELLOSE 2910 (3 MPA.S)</b> (UNII: 0VUT3PMY82)	
<b>HYPROMELLOSE 2910 (6 MPA.S)</b> (UNII: 0WZ8WG20P6)	
<b>MAGNESIUM STEARATE</b> (UNII: 70097M6I30)	
<b>MICROCRYSTALLINE CELLULOSE</b> (UNII: OP1R32D61U)	
<b>POLYETHYLENE GLYCOL 400</b> (UNII: B697894SGQ)	
<b>POLYSORBATE 80</b> (UNII: 6OZP39ZG8H)	
<b>POVIDONE, UNSPECIFIED</b> (UNII: FZ989GH94E)	
<b>TALC</b> (UNII: 7SEV7J4R1U)	
<b>TITANIUM DIOXIDE</b> (UNII: 15FIX9V2JP)	

### Product Characteristics

<b>Color</b>	WHITE	<b>Score</b>	no score
<b>Shape</b>	OVAL	<b>Size</b>	19mm
<b>Flavor</b>		<b>Imprint Code</b>	GGC9
<b>Contains</b>			

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA202588	03/04/2014	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA202588	03/04/2014	

**Labeler** - Sandoz Inc (005387188)

Revised: 7/2021

Sandoz Inc